Bangalore-headquartered Indegene Lifesystems Pvt Ltd, which provides clinical, commercial and marketing solutions to life sciences and pharmaceutical companies, has acquired SmartCare, a health analytics platform from Connecticut-based Vantage Point, Inc, the company’s CEO told VCCircle.
The deal, which is valued at $6-8 million, will go out in
trenches in three years given the positive outcomes from
said Manish Gupta, co-founder and CEO of Indegene.
VCCircle had first reported on August 17 that Indegene was close to buying two US-based health-tech firms. Gupta had said the target companies are in the revenue range of $5-10 million.
The acquisition expands our capability to provide solutions
that impact more than 3 million lives in the US and will
help our revenues grow more than 100 per cent year on year
for three to five years,
Gupta said. An IIT-BHU and IIM Ahmedabad alumnus, Gupta had
previously worked with Infosys. Indegene has struck a few
acquisitions in the past.
SmartCare allows decision makers the ability to monitor clinical, operational and financial metrics with ease. It merges data types including clinical and claims data, membership and eligibility files, drug prescriptions and lab tests into a single database.
We are happy to ally with Indegene in bringing about this
transformation in population health analytics and patient
said Lawrence S Borok, CEO and president at Vantage Point,
Indegene, which helps US-based life sciences companies through its analytics, technology, operations and medical expertise (ATOM), has recently turned its focus on the medical insurance space. Gupta claimed Indegene is in the nearly $100 million revenue range and aims to touch $250 million in five years.
The company has around 1,400 employees and offices in Montreal, Los Angeles, Atlanta, Shanghai, Zurich and Bangalore. It was catering to the domestic market till 2004 and later decided to change its strategy to focus on the overseas market. A little later, Infosys co-founder NS Raghavan's Nadathur Holdings invested in the firm offering an exit to KITVEN Fund, which had invested in Indegene in 2002.
For more details please refer to